All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Adalimumab
Therapeutic Area: Immunology Product Name: HLX03
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
Adalimumab is the third monoclonal antibody developed by Henlius and approved in China, after the Company's rituximab biosimilar HLX01, and trastuzumab biosimilar HLX02, the first China-developed mAb biosimilar approved both in China and in the EU.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Adalimumab
Therapeutic Area: Immunology Product Name: Sulinno
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
SULINNO® (adalimumab injection) is a recombinant human anti-TNF-α monoclonal antibody drug approved by the china NMPA for the treatment of polyarticular juvenile idiopathic arthritis (pJIA). This is the fourth approved indication of SULINNO® in China.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Adalimumab
Therapeutic Area: Immunology Product Name: Sulinno
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020
Details:
SULINNO® (adalimumab injection), a recombinant human anti-TNF-α monoclonal antibody drug, has been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis in China.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
